Host genetic variants in obesity-related nonalcoholic fatty liver disease

Clinics in Liver Disease

Volumn 18, Issue 1, 2014, Pages 249-267

  Mehta, Rohini ^a   Birerdinc, Aybike ^a,b   Younossi, Zobair M ^a,c  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

^c INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

GWAS; Polymorphism; SNP; Steatosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADIPONECTIN; ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR; FATTY ACID TRANSPORTER; FATTY ACID TRANSPORTER 5; LEPTIN RECEPTOR; LIPIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLETHANOLAMINE METHYLTRANSFERASE; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOGENESIS; DISEASE PREDISPOSITION; FIBROSIS; FOOD INTAKE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEMOCHROMATOSIS; HUMAN; INFLAMMATION; LIPID METABOLISM; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

GWAS; POLYMORPHISM; SNP; STEATOSIS;

ADIPOGENESIS; APOLIPOPROTEIN C-III; CARRIER PROTEINS; FATTY LIVER; GENETIC ASSOCIATION STUDIES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LIPASE; LIPID METABOLISM; LIVER; MEMBRANE PROTEINS; OBESITY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PHOSPHATIDATE PHOSPHATASE; PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC, BETA; TRIGLYCERIDES;

EID: 84888023933     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2013.09.017     Document Type: Review

References (99)

1. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34(3):274-285. 10.1111/j.1365-2036.2011.04724.x.
2. Charlton M.R., Burns J.M., Pedersen R.A., et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011, 141(4):1249-1253. 10.1053/j.gastro.2011.06.061.
3. Mehta R., Younossi Z.M. Natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2012, 1(4):111-112. 10.1002/cld.27.
4. Lazo M., Hernaez R., Eberhardt M.S., et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013, 10.1093/aje/kws448.
5. Caballería L., Pera G., Auladell M.A., et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur J Gastroenterol Hepatol 2010, 22(1):24-32. 10.1097/MEG.0b013e32832fcdf0.
6. Alam S., Noor-E-Alam S.M., Chowdhury Z.R., et al. Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh. World J Hepatol 2013, 5(5):281-287. 10.4254/wjh.v5.i5.281.
7. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40(6):1387-1395. 10.1002/hep.20466.
8. Marcos A., Fisher R.A., Ham J.M., et al. Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation 2000, 69(11):2410-2415.
9. Duvnjak M., Barsic N., Tomasic V., et al. Genetic polymorphisms in non-alcoholic fatty liver disease: clues to pathogenesis and disease progression. World J Gastroenterol 2009, 15(48):6023-6027. 10.3748/wjg.15.6023.
10. Amarapurkar D., Kamani P., Patel N., et al. Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol 2007, 6(3):161-163.
11. Lee J.Y., Kim K.M., Lee S.G., et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. JHepatol 2007, 47(2):239-244. 10.1016/j.jhep.2007.02.007.
12. Hooper A.J., Adams L.A., Burnett J.R. Genetic determinants of hepatic steatosis in man. JLipid Res 2011, 52(4):593-617. 10.1194/jlr.R008896.
13. Adams L.A., White S.W., Marsh J.A., et al. Association between liver-specific gene polymorphisms and their expression levels with nonalcoholic fatty liver disease. Hepatology 2013, 57(2):590-600. 10.1002/hep.26184.
14. Lewis C.M., Knight J. Introduction to Genetic Association Studies. Cold Spring Harb Protoc 2012, 2012(3). pdb.top068163. 10.1101/pdb.top068163.
15. Hernaez R. Genetic factors associated with the presence and progression of nonalcoholic fatty liver disease: a narrative review. Gastroenterol Hepatol 2012, 35(1):32-41. 10.1016/j.gastrohep.2011.08.002.
16. McHutchison J.G. The role of genetic markers in hepatitis C virus therapy: a major step for individualized care. Liver Int 2011, 31:29-35. 10.1111/j.1478-3231.2010.02389.x.
17. Romeo S., Kozlitina J., Xing C., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008, 40(12):1461-1465. 10.1038/ng.257.
18. Speliotes E.K., Yerges-Armstrong L.M., Wu J., et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011, 7(3):e1001324.
19. Sharp D., Ricci B., Kienzle B., et al. Human microsomal triglyceride transfer protein large subunit gene structure. Biochemistry 1994, 33(31):9057-9061.
20. Lehner R., Lian J., Quiroga A.D. Lumenal lipid metabolism implications for lipoprotein assembly. Arterioscler Thromb Vasc Biol 2012, 32(5):1087-1093. 10.1161/ATVBAHA.111.241497.
21. Hagan D.L., Kienzle B., Jamil H., et al. Transcriptional regulation of human and hamster microsomal triglyceride transfer protein genes. Cell type-specific expression and response to metabolic regulators. JBiol Chem 1994, 269(46):28737-28744.
22. Aminoff A., Ledmyr H., Thulin P., et al. Allele-specific regulation of MTTP expression influences the risk of ischemic heart disease. JLipid Res 2010, 51(1):103-111. 10.1194/jlr.M900195-JLR200.
23. Ledmyr H., Karpe F., Lundahl B., et al. Variants of the microsomal triglyceride transfer protein gene are associated with plasma cholesterol levels and body mass index. JLipid Res 2002, 43(1):51-58.
24. Peng X.E., Wu Y.L., Lu Q.Q., et al. MTTP polymorphisms and susceptibility to non-alcoholic fatty liver disease in a Han Chinese population. Liver Int 2013, 10.1111/liv.12220.
25. Briggs M.R., Yokoyama C., Wang X., et al. Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. I. Identification of the protein and delineation of its target nucleotide sequence. JBiol Chem 1993, 268(19):14490-14496.
26. Rubin D., Schneider-Muntau A., Klapper M., et al. Functional analysis of promoter variants in the microsomal triglyceride transfer protein (MTTP) gene. Hum Mutat 2008, 29(1):123-129. 10.1002/humu.20615.
27. Karpe F., Lundahl B., Ehrenborg E., et al. Acommon functional polymorphism in the promoter region of the microsomal triglyceride transfer protein gene influences plasma LDL levels. Arterioscler Thromb Vasc Biol 1998, 18(5):756-761.
28. Bernard S., Touzet S., Personne I., et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 2000, 43(8):995-999. 10.1007/s001250051481.
29. Namikawa C., Shu-Ping Z., Vyselaar J.R., et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. JHepatol 2004, 40(5):781-786. 10.1016/j.jhep.2004.01.028.
30. Gambino R., Cassader M., Pagano G., et al. Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH?. Hepatology 2007, 45(5):1097-1107. 10.1002/hep.21631.
31. Oliveira C.P., Stefano J.T., Cavaleiro A.M., et al. Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease. JGastroenterol Hepatol 2010, 25(2):357-361. 10.1111/j.1440-1746.2009.06001.x.
32. Corbin K.D., Zeisel S.H. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol 2012, 28(2):159-165. 10.1097/MOG.0b013e32834e7b4b.
33. Watkins S.M., Zhu X., Zeisel S.H. Phosphatidylethanolamine-N-methyltransferase activity and dietary choline regulate liver-plasma lipid flux and essential fatty acid metabolism in mice. JNutr 2003, 133(11):3386-3391.
34. Song J., da Costa K.A., Fischer L.M., et al. Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB J 2005, 19(10):1266-1271. 10.1096/fj.04-3580com.
35. Dong H., Wang J., Li C., et al. The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population. JHepatol 2007, 46(5):915-920. 10.1016/j.jhep.2006.12.012.
36. Romeo S., Cohen J.C., Hobbs H.H. No association between polymorphism in PEMT (V175M) and hepatic triglyceride content in the Dallas Heart Study. FASEB J 2006, 20(12):2180. [author reply: 2181-2]. 10.1096/fj.06-1004ufm.
37. Duseja A., Aggarwal R. APOC3 and PNPLA3 in non-alcoholic fatty liver disease: need to clear the air. JGastroenterol Hepatol 2012, 27(5):848-851. 10.1111/j.1440-1746.2012.07103.x.
38. Yuan X., Waterworth D., Perry J.R., et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet 2008, 83(4):520-528. 10.1016/j.ajhg.2008.09.012.
39. Romeo S., Sentinelli F., Dash S., et al. Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. Int J Obes 2010, 34(1):190-194. 10.1038/ijo.2009.216.
40. Valenti L., Al-Serri A., Daly A.K., et al. Homozygosity for the PNPLA3/adiponutrin I148 M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010, 51:1209-1217.
41. Sookoian S., Pirola C.J. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011, 53(6):1883-1894. 10.1002/hep.24283.
42. Kotronen A., Johansson L.E., Johansson L.M., et al. Acommon variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009, 52(6):1056-1060. 10.1007/s00125-009-1285-z.
43. Beer N.L., Tribble N.D., McCulloch L.J., et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 2009, 18(21):4081-4088. 10.1093/hmg/ddp357.
44. Li W.W., Dammerman M.M., Smith J.D., et al. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. JClin Invest 1995, 96(6):2601-2605. 10.1172/JCI118324.
45. Miller M., Rhyne J., Chen H., et al. APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome. Arch Med Res 2007, 38(4):444-451. 10.1016/j.arcmed.2006.10.013.
46. Pollex R.L., Ban M.R., Young T.K., et al. Association between the -455T>C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample. BMC Med Genet 2007, 8(1):80. 10.1186/1471-2350-8-80.
47. Petersen K.F., Dufour S., Hariri A., et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. NEngl J Med 2010, 362(12):1082-1089. 10.1056/NEJMoa0907295.
48. Valenti L., Nobili V., Al-Serri A., et al. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. JHepatol 2011, 55(6):1409-1414. 10.1016/j.jhep.2011.03.035.
49. Chen S., Li Y., Li S., et al. AVal227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio. JGastroenterol Hepatol 2008, 23(9):1415-1418. 10.1111/j.1440-1746.2008.05523.x.
50. Rosca M.G., Vazquez E.J., Chen Q., et al. Oxidation of fatty acids is the source of increased mitochondrial reactive oxygen species production in kidney cortical tubules in early diabetes. Diabetes 2012, 61(8):2074-2083. 10.2337/db11-1437.
51. Sparsø T., Hussain M.S., Andersen G., et al. Relationships between the functional PPARα Leu162Val polymorphism and obesity, type 2 diabetes, dyslipidaemia, and related quantitative traits in studies of 5799 middle-aged white people. Mol Genet Metab 2007, 90(2):205-209. 10.1016/j.ymgme.2006.10.007.
52. Dongiovanni P., Rametta R., Fracanzani A., et al. Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. BMC Gastroenterol 2010, 10(1):102.
53. Yoneda M., Hotta K., Nozaki Y., et al. Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol 2008, 8:27. 10.1186/1471-230X-8-27.
54. Hui Y., Yu-Yuan L., Yu-Qiang N., et al. Effect of peroxisome proliferator-activated receptors-γ and co-activator-1α genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people. Liver Int 2008, 28(3):385-392. 10.1111/j.1478-3231.2007.01623.x.
55. Rey J.W. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ2 in patients with fatty liver diseases. World J Gastroenterol 2010, 16(46):5830. 10.3748/wjg.v16.i46.5830.
56. Reue K., Zhang P. The lipin protein family: dual roles in lipid biosynthesis and gene expression. FEBS Lett 2008, 582(1):90-96. 10.1016/j.febslet.2007.11.014.
57. Valenti L., Motta B.M., Alisi A., et al. LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease. JPediatr Gastroenterol Nutr 2012, 54(5):588-593. 10.1097/MPG.0b013e3182442a55.
58. Doege H., Grimm D., Falcon A., et al. Silencing of hepatic fatty acid transporter protein 5 invivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia. JBiol Chem 2008, 283(32):22186-22192. 10.1074/jbc.M803510200.
59. Auinger A., Valenti L., Pfeuffer M., et al. Apromoter polymorphism in the liver-specific fatty acid transport protein 5 is associated with features of the metabolic syndrome and steatosis. Horm Metab Res 2010, 42(12):854-859. 10.1055/s-0030-1267186.
60. Merika M., Orkin S.H. DNA-binding specificity of GATA family transcription factors. Mol Cell Biol 1993, 13(7):3999-4010.
61. Wingender E., Dietze P., Karas H., et al. TRANSFAC: a database on transcription factors and their DNA binding sites. Nucleic Acids Res 1996, 24(1):238-241.
62. Liggett S.B. Pharmacogenetics of beta-1- and beta-2-adrenergic receptors. Pharmacology 2000, 61(3):167-173. doi:28397.
63. Nozaki Y., Saibara T., Nemoto Y., et al. Polymorphisms of interleukin-1 beta and beta 3-adrenergic receptor in Japanese patients with nonalcoholic steatohepatitis. Alcohol Clin Exp Res 2004, 28(8 Suppl Proceedings):106S-110S.
64. Iwamoto N., Ogawa Y., Kajihara S., et al. Gln27Glu β2-adrenergic receptor variant is associated with hypertriglyceridemia and the development of fatty liver. Clin Chim Acta 2001, 314(1-2):85-91. 10.1016/S0009-8981(01)00633-7.
65. Daghestani M.H., Warsy A., Daghestani M.H., et al. The Gln27Glu polymorphism in β2-adrenergic receptor gene is linked to hypertriglyceridemia, hyperinsulinemia and hyperleptinemia in Saudis. Lipids Health Dis 2010, 9(1):90. 10.1186/1476-511X-9-90.
66. Lee U.E., Friedman S.L. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011, 25(2):195-206. 10.1016/j.bpg.2011.02.005.
67. Day C.P. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int 2006, 26(9):1021-1028. 10.1111/j.1478-3231.2006.01323.x.
68. Sazci A., Ergul E., Aygun C., et al. Methylenetetrahydrofolate reductase gene polymorphisms in patients with nonalcoholic steatohepatitis (NASH). Cell Biochem Funct 2008, 26(3):291-296. 10.1002/cbf.1424.
69. Siqueira E.R., Oliveira C.P., Muniz M.T., et al. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and high plasma homocysteine in chronic hepatitis C (CHC) infected patients from the northeast of Brazil. Nutr J 2011, 10(1):86. 10.1186/1475-2891-10-86.
70. Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis 2010, 28(1):179-185. 10.1159/000282083.
71. Frigerio S., Ciusani E., Pozzi A., et al. Tumor necrosis factor microsatellite polymorphisms in Italian glioblastoma patients. Cancer Genet Cytogenet 1999, 109(2):172-174.
72. Valenti L., Fracanzani A.L., Dongiovanni P., et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002, 122(2):274-280.
73. Tokushige K., Takakura M., Tsuchiya-Matsushita N., et al. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. JHepatol 2007, 46(6):1104-1110. 10.1016/j.jhep.2007.01.028.
74. Wang J., Feng Z., Li Y., et al. Association of tumor necrosis factor-α gene promoter polymorphism at sites -308 and -238 with non-alcoholic fatty liver disease: a meta-analysis. JGastroenterol Hepatol 2012, 27(4):670-676. 10.1111/j.1440-1746.2011.06978.x.
75. Dixon J.B., Bhathal P.S., Jonsson J.R., et al. Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. JHepatol 2003, 39(6):967-971.
76. Zain S.M., Mohamed Z., Mahadeva S., et al. Susceptibility and gene interaction study of the angiotensin ii type 1 receptor (AGTR1) gene polymorphisms with non-alcoholic fatty liver disease in a multi-ethnic population. PLoS One 2013, 8(3):e58538. 10.1371/journal.pone.0058538.
77. Yoneda M., Hotta K., Nozaki Y., et al. Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. Liver Int 2009, 29(7):1078-1085. 10.1111/j.1478-3231.2009.01988.x.
78. Nabeshima Y., Tazuma S., Kanno K., et al. Deletion of angiotensin II type I receptor reduces hepatic steatosis. JHepatol 2009, 50(6):1226-1235. 10.1016/j.jhep.2009.01.018.
79. Lu H., Sun J., Sun L., et al. Polymorphism of human leptin receptor gene is associated with type 2 diabetic patients complicated with non-alcoholic fatty liver disease in China. JGastroenterol Hepatol 2009, 24(2):228-232. 10.1111/j.1440-1746.2008.05544.x.
80. Zain S.M., Mohamed Z., Mahadeva S., et al. Impact of leptin receptor gene variants on risk of non-alcoholic fatty liver disease and its interaction with adiponutrin gene. JGastroenterol Hepatol 2013, 28(5):873-879. 10.1111/jgh.12104.
81. Aller R., De Luis D.A., Izaola O., et al. Lys656Asn polymorphism of leptin receptor, leptin levels and insulin resistance in patients with non alcoholic fatty liver disease. Eur Rev Med Pharmacol Sci 2012, 16(3):335-341.
82. Polyzos S.A., Kountouras J., Zavos C., et al. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 2010, 12(5):365-383. 10.1111/j.1463-1326.2009.01176.x.
83. Tokushige K., Hashimoto E., Noto H., et al. Influence of adiponectin gene polymorphisms in Japanese patients with non-alcoholic fatty liver disease. JGastroenterol 2009, 44(9):976-982. 10.1007/s00535-009-0085-z.
84. Wong V.W., Wong G.L., Tsang S.W., et al. Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people. JGastroenterol Hepatol 2008, 23(6):914-921. 10.1111/j.1440-1746.2008.05344.x.
85. Musso G., Gambino R., De Michieli F., et al. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: possible pathogenetic role in NASH. Hepatology 2008, 47(4):1167-1177. 10.1002/hep.22142.
86. Wang Z.L., Xia B., Shrestha U., et al. Correlation between adiponectin polymorphisms and non-alcoholic fatty liver disease with or without metabolic syndrome in Chinese population. JEndocrinol Invest 2008, 31(12):1086-1091.
87. Guyader D., Deugnier Y. Steatosis, iron and HFE genes. JHepatol 2008, 48(3):514-515. 10.1016/j.jhep.2007.12.002.
88. Ahmed U., Latham P.S., Oates P.S. Interactions between hepatic iron and lipid metabolism with possible relevance to steatohepatitis. World J Gastroenterol 2012, 18(34):4651-4658. 10.3748/wjg.v18.i34.4651.
89. Feder J.N., Gnirke A., Thomas W., et al. Anovel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996, 13(4):399-408. 10.1038/ng0896-399.
90. Scott J.D., Garland N. Chronic liver disease in aboriginal North Americans. World J Gastroenterol 2008, 14(29):4607-4615. 10.3748/wjg.14.4607.
91. Hernaez R., Yeung E., Clark J.M., et al. Hemochromatosis gene and nonalcoholic fatty liver disease: a systematic review and meta-analysis. JHepatol 2011, 55(5):1079-1085. 10.1016/j.jhep.2011.02.013.
92. Mura C., Raguenes O., Férec C. HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood 1999, 93(8):2502-2505.
93. Wallace D.F., Walker A.P., Pietrangelo A., et al. Frequency of the S65C mutation of HFE and iron overload in 309 subjects heterozygous for C282Y. JHepatol 2002, 36(4):474-479.
94. Bonkovsky H.L., Jawaid Q., Tortorelli K., et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. JHepatol 1999, 31(3):421-429. 10.1016/S0168-8278(99)80032-4.
95. George D.K., Goldwurm S., MacDonald G.A., et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998, 114(2):311-318.
96. Chitturi S., Weltman M., Farrell G.C., et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002, 36(1):142-149. 10.1053/jhep.2002.33892.
97. Lee S.H., Jeong S.-H., Lee D., et al. An epidemiologic study on the incidence and significance of HFE mutations in a Korean cohort with nonalcoholic fatty liver disease. JClin Gastroenterol 2010, 44(7):e154-e161. 10.1097/MCG.0b013e3181d347d9.
98. Raszeja-Wyszomirska J., Kurzawski G., Lawniczak M., et al. Nonalcoholic fatty liver disease and HFE gene mutations: a Polish study. World J Gastroenterol 2010, 16(20):2531-2536. 10.3748/wjg.v16.i20.2531.
99. Lvovs D., Favorova O.O., Favorov A.V. Apolygenic approach to the study of polygenic diseases. Acta Naturae 2012, 4(3):59-71.